REG - EKF Diagnostics Hldg - H1 2025 Trading Update

EKF Diagnostics HoldingsAnnouncement

Mon 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250728:nRSb6843Sa&default-theme=true

RNS Number : 6843S  EKF Diagnostics Holdings PLC  28 July 2025

 

EKF Diagnostics Holdings plc

("EKF" or the "Company")

 

H1 2025 Trading Update

 

Continued improvement in earnings and cash generation

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-quoted global diagnostics
business, provides an unaudited trading update for the six months ended 30
June 2025 ("H1 2025"), a period showing further improvement in gross margins,
earnings growth and cash generation, in-line with management expectations.

 

H1 2025 revenues were £25.2m (H1 2024: £25.2m), in-line with management
expectations following completion of the rationalisation process last year
which enabled a greater commercial focus on higher margin products and
services. As a result, gross margins further improved to 50% (H1 2024: 48%)
and adjusted EBITDA(1) showed continued growth. In constant currency terms,
revenues and adjusted EBITDA grew year-on-year by 2% and 9% respectively.

 

Strong cash generation continued with cash balances as at 30 June 2025 of
£16.9m (31 December 2024: £14.3m), including cash balances in Russia of
£1.9m (31 December 2024: £1.3m). The Company has no bank borrowings and cash
balances are after the deployment of £1m of on-market purchases in the
initial share buyback programme, and the continued investment for growth that
is part of the five-year strategic development plan for the business.

 

The implementation of the five-year plan continues in-line with management
expectations, with a strong revenue performance from the key growth areas of
Hematology (8% increase year-on-year) and β-HB (12% increase year-on-year).
Diabetes sales have stabilised providing a steady performance in the first
half. The pipeline for contract manufacturing and fermentation opportunities
is encouraging with a number of high value prospects now in the advanced stage
of discussions. The Company hopes to update shareholders on the conversion of
these opportunities in due course.

 

The Company remains on track to deliver growth at the revenue and adjusted
EBITDA levels for FY 2025 in-line with market expectations(2).

 

EKF will announce unaudited results for H1 2025 on 16 September 2025.

 

(1)Earnings before interest, tax, depreciation and amortisation, excluding
exceptional items.

²Management understands consensus revenue and Adjusted EBITDA forecasts for
FY 2025 to be £53.6m and £12.4m respectively.

 

The person responsible for arranging the release of this Announcement

on behalf of the Company is Gavin Jones, Chief Executive Officer.

 

 EKF Diagnostics Holdings plc                                www.ekfdiagnostics.com (http://www.ekfdiagnostics.com)
 Julian Baines, Executive Chair                               via Walbrook PR
 Gavin Jones, Chief Executive Officer
 Stephen Young, Chief Financial Officer

 Singer Capital Markets (Nominated Adviser & Broker)                                       Tel: +44 (0)20 7496 3000
 Phil Davies / Oliver Platts

 Walbrook PR Limited              Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com (mailto:ekf@walbrookpr.com)
 Paul McManus / Alice Woodings    Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com
(http://www.ekfdiagnostics.com) )

 

EKF is an AIM-listed global diagnostics business focussed on:

 

 ●    Point-of-Care analysers in the key areas of Hematology and Diabetes
 ●    Life Sciences services provide specialist manufacture of enzymes and custom
      products for use in diagnostic, food and industrial applications.

 

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing
sites across the US and Germany, selling into over 120 countries world-wide.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTPKPBDABKDOOB